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Abstract In Alpha-mannosidosis (MIM 248500) the
patients accumulate mainly unbranched oligosaccharide
chains in the lysosomes in all body tissues, including the
brain. With ensuing therapeutic modalities in man (BMT
and ERT) non-invasive methods of monitoring the effect of
treatment are needed. Paramount is the possible effect of
the treatment on the brain, since this organ is regarded as
difficult to reach because of the blood-brain barrier. We
therefore performed proton nuclear magnetic resonance
spectroscopy (MRS) of the brain in two untreated patients,
and a 16-year-old patient treated with BMT at the age of 10
to assess whether this non-invasive method could be applied
in the monitoring of the accumulation of abnormal chemicals
in the brain of patients. We found an abnormal peak that was
not present in the treated patient. A similar pattern was also
found in MRS of urine from patients, reflecting the
concentration of oligosaccharides in serum and tissues. We
therefore conclude that MRS can be a useful method to
monitor the effect of treatment for Alpha-Mannosidosis.
Introduction
Alpha-Mannosidosis (MIM 248500) is an autosomal
recessive lysosomal storage disorder resulting from defi-
cient activity of lysosomal alpha-mannosidase. Affected
patients accumulate mainly unbranched oligosaccharide
chains in the lysosomes, of which the major storage
product is the trisaccharide Manα1-3Manβ1-4GlcNAc
(Michalski et al. 1990). Patients accumulate mannose-rich
oligosaccharides in serum and most tissues. They suffer
from mental retardation, immune deficiency and skeletal
deformities (Øckermann 1967).
In parallel with the management of Gaucher disease with
enzyme replacement therapy (ERT), several studies to
investigate the effect of ERT in mannosidosis with
recombinant enzyme have been performed in mice (Stinchi
et al. 1999) or in guinea pigs (Berg and Hopwood 2002).
The effect of the treatment on cerebral and extra-cerebral
functions has been assessed by studying histology in tissues
after sacrificing the animals (Roces et al. 2004;D ’Hooge et
al. 2005). In addition bone marrow transplants (BMT) have
been performed in cats (Walkley et al. 1994) and man (Wall
et al 1998). BMT has been considered a likely success,
although the number of patients is small and measured
parameters “soft” (Grewal et al. 2004). With ensuing
therapeutic modalities in man (BMT and ERT), non-
invasive methods of monitoring the effect of treatment are
needed. Paramount is the possible effect of the treatment on
the brain, since this organ is regarded difficult to reach
because of the blood-brain barrier (Johanson et al. 2011).
We therefore performed proton magnetic nuclear reso-
nance spectroscopy of the brain in two untreated patients,
and a 16-year-old patient treated with BMTat the age of 10,
to test whether this non-invasive method could be applied
in the monitoring of the accumulation of abnormal
chemicals in the brain of patients.
In MR imaging, one uses the signal from water and fat
protons to create an image. MRS is a method of detecting
certain metabolites that are not used in normal MR imaging
due to their low concentrations and the difference in their
resonance frequencies from water and fat. In single voxel
MRS all the signal coming from one defined volume is
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displayed as different peaks on their specific resonance
frequencies. These frequencies are expressed as parts per
million (ppm) differences from a standard. A typical
substance like N-acetylaspartate (NAA) will thus always be
displayed at 2.0 ppm. This makes it possible to identify the
differentmolecules.The relativeamountofsignalisdisplayed
as the peak height, and its relation to other metabolites is
studied with peak height ratios calculation. For these
calculations an internal reference (the Creatine peak height
at 3 ppm) is often used since this signal has been shown to be
relatively stable. For absolute quantification of the MRS
signal,one coulduse anexternalreference but thisisnormally
not done. Modern MR Scanners are now able to perform an
MRS scan within a few minutes with automatic data analysis,
making it possible to examine many patients without the need
for sedation. It is now part of routine scanning in many
institutions. However many younger patients will often not be
able to comply with prolonged scanning times and would still
need sedation.
Methods
In two untreated patients (age 36 and age 20) and one BMT
treated patient (age 16) routine unsedated MR imaging was
supplied with single voxel proton spectroscopy on a 1.5
Tesla whole body Philips scanner. All examinations were
performed after informed consent was obtained from the
subjects or their parents. Single voxel proton spectroscopy
was performed with short 22-30 ms and intermediate
136 ms and longer echo-times with PRESS technique, in
the basal ganglia, periventricular white matter and occipital
grey matter. Due to relatively long examination times for
spectroscopy not all areas were examined in all patients.
Fasting early morning urine samples from the BMT
treated patient and from an untreated patient were examined
with in vitro spectroscopy to verify the in vivo findings.
The in vitro spectroscopy was performed on a Varian Inova
NMR spectrometer with field strength of 14 Tesla, using
PRESAT water suppression.
Our patients displayed a uniform disease presentation that
started in the first year of life and which included immune
deficiency, hearing deficits, mental retardation, and skeletal
deformities.One patient wastreatedwithBMTatage 10;with
the engraftment proven to be 100% one year later.
Results
The MR imaging done prior to the spectroscopy uptake did
not show any focal lesions. One patient had a narrow
foramen magnum and some tonsillar descent.
Representative proton spectra from a voxel placed in
the basal ganglia, with short echo times are shown in
Fig. 1.
The analysis of the spectra is summarized in Table 1.
The short echo times spectra show a broad elevation of
the peaks around 3.7 ppm as well as some increase of the
Fig. 1 Upper spectrum: short echo-time proton spectroscopy of a
20 year old untreated patient taken in the region of the basal ganglia,
with a broad elevation around 3.7 ppm.(arrow). Middle spectrum:
short echo-time proton spectroscopy of a BMT treated patient taken in
the region of the basal ganglia , with a mild broad elevation around
3.7 ppm (arrow) and somewhat elevated second Creatine peak at
3.9 ppm. Lower spectrum: Short echo-time proton spectroscopy of a
control subject showing a normal spectrum, with normal amount of
signal where our patients showed increased signal (arrow)
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pronounced in the untreated patients but still visible in the
BMT treated patient. The pathological increase of signal in
our patients disappeared at intermediate and long echo-
times (136 ms and longer), and spectra obtained with these
echo times had normalized (not shown).
In vitro spectroscopy of urine samples from an untreated
and a BMT treated patient show extra peaks from 3.6 to
3.8ppmmostprobablyrepresentingthesameoligosaccharides
(Fig. 2).
Discussion
Ever since the introduction of magnetic resonance, the
brain of patients with Alpha-Mannosidosis and other
lysosomal storage diseases has been studied, first with
morphologic imaging (Patlas et al. 2001; Autti et al.
2007;S e t oe ta l .2001) and later with functional MR
imaging such as diffusion weighting (Patay 2005). These
imaging methods have the potential to show the damage or
developmental disturbances due to these diseases, but it is
only by MRS one can attempt to measure the amount of
accumulated oligosaccharides and other molecules. Func-
tional neuron distribution of N-acetylaspartate (NAA) was
studied in 60 patients with Mucopolysaccharidosis (MPS)
and was shown to be decreased in lesions visible on
standard imaging (Takahashi et al. 2001; Vendolin et al.
2007), whereas Myo-inositol (3.6 ppm) a marker of
gliosis, was found to be increased within lesions. A more
recent study of a cat model of alpha-mannosidosis
(Magnitsky et al. 2010) examined the brain of normal
and affected cats with high field (4.7 Tesla) MRS. They
showed that the MRS spectra had the same properties as
those spectra in MPS patients with broad high peaks at
3.7 ppm. They could also distinguish an additional smaller
peak at around 2 ppm.
The increase in signal in our Mannosidosis patients is
best shown on short echo-time spectra due to the short
relaxation times of the metabolites. A short relaxation time
means that the signal disappears faster than other metabo-
lites. At these longer echo-times most of the oligosacchar-
ides as well as glutamate, glutamine, lipids, and myo-
inositol will not show any signal. In clinical practice, when
studying diseases related to molecules with short relaxation
times, only short echo time spectra are considered, as we
have done here. To describe eventual abnormalities, an
internal reference is used (Cr) and peak to peak ratios or
areas are calculated and compared. These ratios are only
measurable in clinical practice on clearly defined non
overlapping peaks. Our patients showed broad areas of
elevation centred at 3.7 ppm, overlapping other metabolites
like Myo-inositol at 3.6 ppm, Alpha glutamine and
Fig. 2 In vitro spectroscopy scan of urine samples from a BMT
treated patient(upper spectrum) and from a untreated patient(bottom
spectrum), showing additional peaks in the untreated patient from 3.57
to 3.79 ppm(arrow) representing the oligosaccharides
Table 1 Analysis of the spectra
Age\sex Treatment Location NAA\Cr Cho\Cr mI\Cr pOS\Cr
Patient 1 16\F BMT BG 1.2 0.9 0.8 1.0
Patient 2 20\F none BG 1.6 0.8 0.8 1.4
WM 1.8 0.9 NA 1.6
Patient 3 36\F none OGM 1.8 0.6 0.8 0.9
Normal values 1.1-1.8 0.5-0.9 0.5-0.7 0.5-0.7
Abbreviations: BG, basal ganglia; WM, white matter; OGM, occipital grey matter; pOS presumptive oligosaccharides. Normal values taken from:
Danielsen ER, Ross B (1999) Magnetic resonance spectroscopy diagnosis of neurological diseases. Chapter 2 Basic Physics of MRS.
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making exact quantification and peak to peak ratio
calculations difficult. Results of these measurements are
shown in Table 1. The range of normal values for NAA is
large in the area of the basal ganglia, the NAA\Cr ranges
from 1.1 in the putamen to 1.8 in white matter. The
additional peak at 2 ppm that was seen in cats at high field
MR was not clearly seen in our patient (Fig. 1) but the
NAA peak shows some broadening here that could be
related to this peak. Further research with higher field
strength is needed to assess this peak. The MRS signal in
our BMT treated patient (Fig. 1) was almost completely
normal which is consistent with the MRS spectra findings
in BMT treated MPS patients (Takahashi et al. 2001). The
broadness of the spectrum due to the different resonances of
the oligosaccharides is also reflected in the urine sample
high field spectroscopy where multiple peaks are observed
at the same resonance frequencies as the in vivo spectra
(Fig. 2).
To our knowledge, this is the first time that MRS is
performed in an Alfa-Mannosidosis patient treated with
BMT. We found a strong pathological signal in an untreated
patient and an almost normal spectrum in the BMT treated
patient.WehavedemonstratedthattheMucopolysaccharidosis
and Oligosaccharidosis patients appear to have abnormal
peaks in the same position on the spectra, and that short echo
time MRS can be used to detect this signal. The ratio of the
pathological signal in MPS patients outside lesions has been
reported to range from0.6-1.5 (Takahashietal. 2001), and our
range was from 0.9 – 1.6. (Table 1).
MRS was performed on three Alfa-Mannosidosis
patients by Gutschalk et al. 2004, and they did not
report any additional peaks. The actual spectra taken are
not shown in their article, but short echo times and
automatic post processing were used and one would
therefore expect to find a pathological peak. One
explanation could be that they examined patients with
the rare adult variant of the disease and that these patients
have a higher residual enzyme capacity and therefore a
reduced accumulation of metabolites. Another explana-
tion could be that the patient group was older (38–
47 years). It is possible that the biochemical environment
or state of the metabolites we are attempting to detect
changes over time and that the MRS features also change.
One of our patients was 36 years of age and we obtained
only one spectrum from occipital grey matter (not
shown), and although there was a clearly pathological
peak its maximum peak height was lower than would be
expected in an individual that had more time to
accumulate oligossacharides. This finding could be
consistent with the findings of Gutschalk et al. 2004.I t
would be necessary to examine patients over time to see if
there exists such an age related pattern.
Conclusion
This study demonstrates that MRS can detect peaks
consistent with carbohydrate moieties in the brain of
patients with Alpha-Mannosidosis. In the BMT treated
patient, 6 years post transplant, an essentially normal
spectrum was obtained. The signal increase measured in
our untreated patients is probably strong enough to be
utilized in monitoring treatment in humans. Further
studies should be performed to evaluate the effect of
BMT (or ERT) in patients being younger at the initiation
of treatment.
Acknowledgements We would like to thank the European Union
HUE-MAN consortium for their cooperation.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Autti T, Joensuu R, Aberg L (2007) Decreased T2 signal in the thalami
may be a sign of lysosomal storage disease. Neuroradiology
49:571–578
Berg T, Hopwood JJ (2002) Alpha-Mannosidosis in the guinea pig:
cloning of the lysosomal alpha-mannosidase cDNA and identi-
fication of a missense mutation causing alpha-mannosidosis.
Biochim Biophys Acta 1586:169–176
Danielsen ER, Ross B (1999) Magnetic resonance spectroscopy
diagnosis of neurological diseases. Marcel Dekker INC, New
York
D'Hooge R, Lullmann-Rauch R, Beckers T, Balschun D, Schwake M,
Reiss K, von Figura K, Saftig P (2005) Neurocognitive and
psychotiform behavioral alterations and enhanced hippocampal
long-term potentiation in transgenic mice displaying neuropath-
ological features of human alpha-mannosidosis. J Neurosci
25:6539–6549
Grewal SS, Shapiro EG, Krivit W, Charnas L, Lockman LA, Delaney
KA, Davies SM, Wenger DA, Rimell FL, Abel S, Grovas AC,
Orchard PJ, Wagner JE, Peters C (2004) Effective treatment of
alpha-mannosidosis by allogeneic hematopoietic stem cell trans-
plantation. J Pediatr 144:569–573
Gutschalk A, Harting I, Cantz M, Springer C, Rohrschneider K,
Meinck H-M (2004) Neurology 63:1744–1746
Johanson CE, Stopa EG, McMillan PN (2011) The blood-
cerebrospinal fluid barrier: structure and functional significance.
Methods Mol Biol 686:101–131
Magnitsky S, Vite CH, Delikatny EJ, Pickup S, Wehrli S, Wolfe JH,
Poptani H (2010) Magnetic resonance spectroscopy of the
occipital cortex and the cerebellar vermis distinguishes individual
cats affected with alpha-mannosidosis from normal cats. NMR
Biomed 23:74–79
Michalski JC, Haeuw JF, Wieruszeski JM, Montreuil J, Strecker G
(1990) In vitro hydrolysis of oligomannosyl oligosaccharides
by the lysosomal alpha-D-mannosidases. Eur J Biochem
189:369–379
1026 J Inherit Metab Dis (2011) 34:1023–1027Ockerman PA (1967) A generalised storage disorder resembling
Hurler's syndrome. Lancet 2:239
Patay Z (2005) Diffusion-weighted MR imaging in leukodystrophies.
Eur Radiol 15:2284–2303
Patlas M, Shapira MY, Nagler A, Sheffer R, Gomori JM (2001) MRI
of mannosidosis. Neuroradiology 43:941–943
Roces DP, Lullmann-Rauch R, Peng J, Balducci C, Andersson C,
Tollersrud O, Fogh J, Orlacchio A, Beccari T, Saftig P, von
Figura K (2004) Efficacy of enzyme replacement therapy in
alpha-mannosidosis mice: a preclinical animal study. Hum Mol
Genet 13:1979–1988
Seto T, Kono K, Morimoto K, Inoue Y, Shintaku H, Hattori H, Matsuoka
O, Yamano T, Tanaka A (2001) Brain magnetic resonance imaging
in 23 patients with mucopolysaccharidoses and the effect of bone
marrow transplantation. Ann Neurol 50:79–92
Stinchi S, Lullmann-Rauch R, Hartmann D, Coenen R, Beccari T,
Orlacchio A, von Figura K, Saftig P (1999) Targeted disruption
of the lysosomal alpha-mannosidase gene results in mice
resembling a mild form of human alpha-mannosidosis. Hum
Mol Genet 8:1365–1372
Takahashi Y, Sukegawa K, Aoki M, Ito A, Suzuki K, Sakaguchi H,
Watanabe M, Isogai K, Mizuno S, Hoshi H, Kuwata K, Tomatsu
S, Kato S, Ito T, Kondo N, Orii T (2001) Evaluation of
accumulated mucopolysaccharides in the brain of patients with
mucopolysaccharidoses by (1)H-magnetic resonance spectrosco-
py before and after bone marrow transplantation. Pediatr Res
49:349–355
Vedolin L, Schwartz IV, Komlos M, Schuch A, Puga AC, Pinto
LL, Pires AP, Giugliani R (2007) Correlation of MR imaging
and MR spectroscopy findings with cognitive impairment in
mucopolysaccharidosis II. AJNR Am J Neuroradiol 28:1029–
1033
Walkley SU, Thrall MA, Dobrenis K, Huang M, March PA, Siegel
DA, Wurzelmann S (1994) Bone marrow transplantation
corrects the enzyme defect in neurons of the central nervous
system in a lysosomal storage disease. Proc Natl Acad Sci
USA 91:2970–2974
Wall DA, Grange DK, Goulding P, Daines M, Luisiri A, Kotagal S
(1998) Bone marrow transplantation for the treatment of alpha-
mannosidosis. J Pediatr 133:282–285
J Inherit Metab Dis (2011) 34:1023–1027 1027